Horizon Pharma (HZNP) Misses Q1 EPS by 2c, Lowers Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Horizon Pharma (HZNP) PT Lowered to $13 at Citi; Remains Positive on Orphan Drug Valuation and Primary Care Earnings
May 9, 2017 7:40 AM EDTCiti lowered its price target on Horizon Pharma (NASDAQ: HZNP) to $13.00 (from $20.00) while maintaining a Buy rating.
Analyst Liav Abraham said results highlight the structural challenges associated with the companys primary care franchise and they acknowledge the limited visibility.
That... More
Mizuho Securities Downgrades Horizon Pharma (HZNP) to Neutral
May 9, 2017 5:21 AM EDTMizuho Securities downgraded Horizon Pharma (NASDAQ: HZNP) from Buy to Neutral with a price target of $10.00 (from $22.00).
Analyst Irina Koffler cites uncertainty revolving around primary business and the lack of guidance conviction for her downgrade.
FY 2017 EPS estimate falls from $2.11 to $0.66... More
